Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy

Jintong Chen, Yinghua Zhao, Xiao Chu, Yong Lu, Siqing Wang, Qing Yi

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cells in vivo. Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.

Original languageEnglish (US)
Article numbere1238558
Issue number11
StatePublished - Nov 1 2016


  • Antitumor immunity
  • Dectin-1
  • dentritic cells
  • Th9
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy'. Together they form a unique fingerprint.

Cite this